CN101264096A - 人参皂苷Rg1的生精作用 - Google Patents

人参皂苷Rg1的生精作用 Download PDF

Info

Publication number
CN101264096A
CN101264096A CNA2007100643260A CN200710064326A CN101264096A CN 101264096 A CN101264096 A CN 101264096A CN A2007100643260 A CNA2007100643260 A CN A2007100643260A CN 200710064326 A CN200710064326 A CN 200710064326A CN 101264096 A CN101264096 A CN 101264096A
Authority
CN
China
Prior art keywords
sperm
gossypol
ginsenoside
group
motility
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2007100643260A
Other languages
English (en)
Other versions
CN101264096B (zh
Inventor
张均田
楚世峰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JICUI HEALTH INDUSTRY CO., LTD.
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN2007100643260A priority Critical patent/CN101264096B/zh
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to ES07846012.8T priority patent/ES2496165T3/es
Priority to JP2009552987A priority patent/JP2010520894A/ja
Priority to PL07846012T priority patent/PL2133082T3/pl
Priority to PT78460128T priority patent/PT2133082E/pt
Priority to PCT/CN2007/003776 priority patent/WO2008110050A1/zh
Priority to DK07846012.8T priority patent/DK2133082T3/da
Priority to US12/530,970 priority patent/US8765695B2/en
Priority to CA2680560A priority patent/CA2680560C/en
Priority to EP07846012.8A priority patent/EP2133082B8/en
Publication of CN101264096A publication Critical patent/CN101264096A/zh
Application granted granted Critical
Publication of CN101264096B publication Critical patent/CN101264096B/zh
Priority to JP2013169853A priority patent/JP2013256519A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

本发明公开了人参皂甙Rg1的制备生精产品的用途。本发明还公开了一种生精的产品，其包括人参皂甙Rg1单体及赋形剂或载体。

Description

人参皂苷Rg1的生精作用
技术领域
本发明涉及人参皂甙Rg1的制备生精产品的用途；本发明还涉及一种生精的产品，其包括人参皂甙Rg1单体及赋形剂或载体。
背景技术
据统计，全世界育龄夫妇中，不孕者约占15％，而不孕因素在男方约占40％，20世纪以来，由于环境污染，性病和艾滋病蔓延，过度吸烟吸毒，滥用激素类药物等因素，全球范围内的男性生育能力有明显下降的趋势，在男性不育症中关键因素之一是精子质量(精子数量和活力)的降低，，寻找改善改善精子质量的药物甚为重要。
本发明的发明人过去的研究已证明人参皂苷Rg1能增强雄性动物的性欲，性功能及阴茎勃起。
发明内容
为了解决现有技术中存在的技术问题，本发明提供了如下技术方案：
本发明提供了人参皂甙Rg1的制备生精产品的用途。
本发明还提供了一种生精的产品，其包括人参皂甙Rg1单体及赋形剂或载体。
本发明的发明人经过系统研究现发现Rg1有促进生精的作用。
已知含于棉子油中的棉酚是一种毒剂，它破坏睾丸组织的生精，致精子数量减少，存活率降低，精子活力下降。本发明的发明人给成年大鼠ip醋酸棉酚建立大鼠生精障碍模型。发明人发现大鼠在给棉酚的同时，每天以不同的剂量灌胃人参皂苷Rg1，能够Rg1显著改善棉酚所致的精子数量减少，存活率降低，精子活力下降，证明Rg1可以增加精子数量，提高精子存活率，增强精子活力。
本发明的发明人进一步研究了人参皂苷Rg1促生精作用的机制。棉酚破坏精子功能主要是干扰精子细胞的变态和中晚期精母细胞的发育，导致精子损伤和曲细精管的萎缩。研究发现棉酚对精子的破坏作用主要是由于它在睾丸组织中产生过量的一氧化氮(NO)，NO作为自由基，一方面破坏生精组织和精子细胞，一方面破坏间质细胞，使睾酮(T)的产生和释放降低。发明人用发射免疫法测定检测睾丸组织内一氧化氮(NO)含量，血清中睾酮(T)，促黄体生成素(LH)，和促卵泡生成素(FSH)。检测结果Rg1可显著降低睾丸组织内过量的NO，从而保护精子免受NO的破坏并升高血中T的含量。而Rg1对血中LH和FSH含量无显著影响(P＞0.05)。
具体实施方式
例1人参皂苷Rg1的促生精作用
成年雄性Wister大鼠，每组10只，共5组。1组为空白对照组，另外4组ip.醋酸棉酚50mg/kg，隔天一次，共七次。一组动物只给棉酚，另三组在给棉酚的同时，每天灌胃人参皂苷Rg1，剂量分别为5，10，15mg/kg，每天一次，共十四次。给药两周后处死动物，取出附睾尾，对精子数量，精子存活率何精子活力进行检测，检测结果如下：
表1人参皂苷Rg1对醋酸棉酚所致精子数量下降的影响
组别   附睾尾精子计数(106/ml)x±s P值
  模型组   110.82±28.59
  空白组(未给棉酚组)   139.27±29.27   ＜0.01
  棉酚+Rg15mg/kg   216.80±31.26   ＜0.01
  棉酚+Rg110mg/kg   256.61±53.73   ＜0.01
  棉酚+Rg115mg/kg   235.49±39.71   ＜0.01
表2人参皂苷Rg1对精子存活率的影响
  组别   精子活率(％)x±s   P值
  模型组   44.52±8.8
  空白组(未给棉酚组)   53.09±7.0   ＜0.05
  棉酚+Rg15mg/kg   44.12±4.79
  棉酚+Rg110mg/kg   62.64±9.94   ＜0.05
  棉酚+Rg115mg/kg   56.69±6.48   ＜0.05
表3人参皂苷Rg1对精子活力的影响
  组别  精子活力(a+b级)(％)x±s   P值
  模型组  29.08±5.97
  空白组(未给棉酚组)  35.58±6.08   ＜0.05
  棉酚+Rg15mg/kg  27.60±5.95
  棉酚+Rg110mg/kg  44.97±8.08   ＜0.01
  棉酚+Rg115mg/kg  36.16±6.55   ＜0.05
按WHO的标准，a级精子是指快速前向运动的精子；b级精子是指慢或呆滞的前向运动的精子；c级精子是指非前向运动的精子；d级精子是指不动者
表1-3的结果说明，醋酸棉酚50mg/kg口服7次可造成精子数量减少，精子存活率降低，精子活力下降，Rg1则可以增加精子数量，提高存活率，增强精子活力，具有明显的改善作用。
例2人参皂苷Rg1促生精作用的机制研究
同时用发射免疫法测定血清中睾酮(T)，促黄体生成素(LH)，和促卵泡生成素(FSH)，并采用南京建成NO试剂盒检测睾丸组织内一氧化氮(NO)含量，具体操作见说明书。
表4.人参皂苷Rg1对睾丸组织一氧化氮(NO)含量的影响
  组别   NO含量(μmol/gpro)x±s   P值
  模型组   20.09±9.42
  空白组(未给棉酚组)   9.48±6.21   ＜0.05
  棉酚+Rg1 5mg/kg   16.01±8.86
  棉酚+Rg1 10mg/kg   9.71±6.79   ＜0.05
  棉酚+Rg1 15mg/kg   10.78±4.58   ＜0.01
表5.人参皂苷Rg1对血清睾酮(T)含量的影响
  组别   T含量(ng/ml)x±s   P值
  模型组   0.28±0.17
  空白组(未给棉酚组)   1,18±1.01   ＜0.05
  棉酚+Rg15mg/kg   0.816±0.32   ＜0.05
  棉酚+Rg110mg/kg   0.97±0.48   ＜0.05
  棉酚+Rg115mg/kg   0.82±0.24   ＜0.01
Rg1可显著降低睾丸组织内过量的NO，从而保护精子免受NO的破坏见表4；升高血中T的含量见。
而Rg1对血中LH和FSH含量无显著影响(P＞0.05)。

Claims (2)

1. 人参皂甙Rg1在制备生精产品中用途。
2. 一种生精的产品，其包括人参皂甙Rg1单体及赋形剂或载体。
CN2007100643260A 2007-03-12 2007-03-12 人参皂苷Rg1在制备生精产品中的应用 Active CN101264096B (zh)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN2007100643260A CN101264096B (zh) 2007-03-12 2007-03-12 人参皂苷Rg1在制备生精产品中的应用
CA2680560A CA2680560C (en) 2007-03-12 2007-12-25 The use of ginsenoside rg1, its metabolites ginsenoside rh1 and/or ppt
PL07846012T PL2133082T3 (pl) 2007-03-12 2007-12-25 Stosowanie ginsenozydu Rg1, jego metabolitów ginsenozydu Rh1 i/lub Ppt
PT78460128T PT2133082E (pt) 2007-03-12 2007-12-25 Utilização do ginsenósido rg1 e dos seus metabolitos ginsenósidos rh1 e ppt
PCT/CN2007/003776 WO2008110050A1 (fr) 2007-03-12 2007-12-25 UTILISATION DE GINSENOSIDE Rg1 ET DE SES MÉTABOLITES GINSENOSIDE Rh1 ET PpT
DK07846012.8T DK2133082T3 (da) 2007-03-12 2007-12-25 Anvendelse af ginsenosid Rg1, dets metabolitter ginsenosid Rh1 og/eller PpT
ES07846012.8T ES2496165T3 (es) 2007-03-12 2007-12-25 El uso del ginsenósido Rg1 y sus metabolitos los ginsenósidos Rh1 y/o PpT
JP2009552987A JP2010520894A (ja) 2007-03-12 2007-12-25 ジンセノサイドＲｇ１、その代謝産物であるジンセノサイドＲｈ１および／またはＰｐｔの使用
EP07846012.8A EP2133082B8 (en) 2007-03-12 2007-12-25 THE USE OF GINSENOSIDE Rg1, ITS METABOLITES GINSENOSIDE Rh1 AND/OR PpT
US12/530,970 US8765695B2 (en) 2007-03-12 2007-12-25 Use of ginsenoside RG1, its metabolites ginsenoside RH1 and/or PPT
JP2013169853A JP2013256519A (ja) 2007-03-12 2013-08-19 ジンセノサイドＲｇ１、その代謝産物であるジンセノサイドＲｈ１および／またはＰｐｔの使用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2007100643260A CN101264096B (zh) 2007-03-12 2007-03-12 人参皂苷Rg1在制备生精产品中的应用

Publications (2)

Publication Number Publication Date
CN101264096A true CN101264096A (zh) 2008-09-17
CN101264096B CN101264096B (zh) 2011-11-09

Family

ID=39758990

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007100643260A Active CN101264096B (zh) 2007-03-12 2007-03-12 人参皂苷Rg1在制备生精产品中的应用

Country Status (10)

Country Link
US (1) US8765695B2 (zh)
EP (1) EP2133082B8 (zh)
JP (2) JP2010520894A (zh)
CN (1) CN101264096B (zh)
CA (1) CA2680560C (zh)
DK (1) DK2133082T3 (zh)
ES (1) ES2496165T3 (zh)
PL (1) PL2133082T3 (zh)
PT (1) PT2133082E (zh)
WO (1) WO2008110050A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643592A (zh) * 2023-11-27 2024-03-05 永创恒新生物医学科技(北京)有限公司 人参皂苷20(R)-25-OH-Rg2促进卵巢修复的用途

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112772630A (zh) * 2020-12-30 2021-05-11 西南大学 一种施氏鲟精子低温保存稀释液及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293664A1 (en) * 1997-06-04 1998-12-10 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Fsh-releasing peptides
US7759101B2 (en) * 2000-12-29 2010-07-20 Fengxie Jin Ginsenoside glycosidases hydrolyzing ginsenoside sugar moieties and uses thereof
US6444237B1 (en) * 2001-09-13 2002-09-03 Pamela A. Heleen Herbal composition for enhancing sexual response
EA007030B1 (ru) * 2001-10-22 2006-06-30 Апплайд Резеч Системз Арс Холдинг Н.В. Гонадотропины для фолликулогенеза
DE10158281A1 (de) * 2001-11-19 2003-05-28 Mediwirk Gmbh Pharmazeutisches Präparat
CN1191071C (zh) * 2002-12-28 2005-03-02 杨淑玲 人参皂苷单体配伍提高性功能的产品
KR100731620B1 (ko) * 2004-05-12 2007-06-22 주식회사 비티진 발기부전 치료를 위한 진세노사이드 조성물
KR20060000488A (ko) 2004-06-29 2006-01-06 홍림통산(주) 인삼 또는 홍삼 추출물, 그의 유산균 발효물 및 그의장내세균 발효물로 이루어진 군으로부터 선택된 1종이상의 인삼 추출물 소양증 예방 및 치료제 조성물
CN102000098B (zh) * 2004-08-11 2015-08-12 中国医学科学院药物研究所 人参皂甙Rg1的用途
CN1795868A (zh) * 2004-12-23 2006-07-05 中国科学院大连化学物理研究所 具有抗衰老活性的药物
TWI369401B (en) * 2005-07-05 2012-08-01 Ares Trading Sa Serum-free culture medium for the production of recombinant gonadotropins

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117643592A (zh) * 2023-11-27 2024-03-05 永创恒新生物医学科技(北京)有限公司 人参皂苷20(R)-25-OH-Rg2促进卵巢修复的用途
CN117643592B (zh) * 2023-11-27 2024-05-28 四川花度蜜美医学研究院 人参皂苷20(R)-25-OH-Rg2促进卵巢修复的用途

Also Published As

Publication number Publication date
WO2008110050A1 (fr) 2008-09-18
EP2133082B8 (en) 2014-07-16
EP2133082B1 (en) 2014-06-11
DK2133082T3 (da) 2014-08-25
CN101264096B (zh) 2011-11-09
CA2680560C (en) 2015-11-24
PL2133082T3 (pl) 2014-11-28
EP2133082A1 (en) 2009-12-16
US20110034403A1 (en) 2011-02-10
EP2133082A4 (en) 2010-03-24
PT2133082E (pt) 2014-09-04
ES2496165T3 (es) 2014-09-18
US8765695B2 (en) 2014-07-01
JP2010520894A (ja) 2010-06-17
CA2680560A1 (en) 2008-09-18
JP2013256519A (ja) 2013-12-26

Similar Documents

Publication Publication Date Title
Coutinho Gossypol: a contraceptive for men
Solter et al. Extrauterine growth of mouse egg-cylinders results in malignant teratoma
Asif A review on spermicidal activities of Azadirachta indica
EP3498280B1 (en) Administration and dosage of therapeutic agent for endometriosis
Ilyas et al. Induction of rat germ cell apoptosis by testosterone undecanoate and depot medroxyprogesterone acetate and correlation of apoptotic cells with sperm concentration
JP3883867B2 (ja) モダフィニル及びそのｄ／ｌ鏡像異性体の新規な使用
CN101264096B (zh) 人参皂苷Rg1在制备生精产品中的应用
Garnier et al. Neuroprotective effects of magnesium on metabolic disturbance in fetal hippocampal slices after oxygen-glucose deprivation: mediation by nitric oxide system
Schwallie et al. Contraceptive use—Efficacy study utilizing Depo-Provera® administered as an injection once every six months
Moskovitz et al. Effect of Diclofenac Sodium (Voltaren) and Prostaglandin E (2) on Spermatogenesis in Mature Dogs
DD238921A5 (de) Verfahren zur herstellung einer kontrazeptiven synergistischen zusammensetzung
Khanduri Fertility control of female rat through Abutilon indicum seeds
Hong et al. The inhibitory effect of gossypol on human sperm motility: relationship with time, temperature and concentration
El Wakeel et al. Effect of ginger on testicular tissue of adult male albino rats treated with mono sodium glutamate (light and electron microscopic studies)
Kumar et al. Aphrodisiac activity of cycas circinalis. l and ionidium suffruticosum. ging on male wister albino rats
Perraud et al. Reproductive studies with the anti-inflammatory agent, piroxicam: modification of classical protocols
KR101317368B1 (ko) 조루증 치료용 한약 조성물
Scales Fertility following synchronization of oestrus in Romney, Corriedale and Merino ewes
RU2519226C1 (ru) Средство для профилактики и лечения андрологических заболеваний и способ его получения
EP4304598A1 (en) Therapeutic composition for erectile dysfunction treatment
Otoo et al. Effect of an ethanolic seed extract of Picralima nitida ((Stapf) Th. & H. Durand) on reproductive abilities and developmental indices in rodents
CN102357099A (zh) 一种含有奥硝唑的药物组合物
Dogra et al. COMPARATIVE EFFICACY OF NORGESTOMET-BASED ESTROUS INDUCTION PROTOCOLS IN BEETAL GOAT
Kuzubova et al. Effects of a new benzimidazole derivative on generative function of female rats
Meldrum et al. Microdose flare versus antagonist for poor responders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: YUNNAN JICUI BIO-TECH CO., LTD.

Free format text: FORMER OWNER: PHARMACOLOGY INST. OF CAMS

Effective date: 20130108

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 100050 XUANWU, BEIJING TO: 675000 CHUXIONG YI AUTONOMOUS PREFECTURE, YUNNANPROVINCE

TR01 Transfer of patent right

Effective date of registration: 20130108

Address after: 675000 Yongan Road, Chuxiong Development Zone, Yunnan, No. 161

Patentee after: Yunnan Jecui Biotechnology Co., Ltd.

Address before: 100050 Beijing city Xuanwu District Xiannongtan Street No. 1

Patentee before: Institute of Materia Medica of Chinese Academy of Medical Sciences

ASS Succession or assignment of patent right

Owner name: JICUI HEALTH INDUSTRY CO., LTD.

Free format text: FORMER OWNER: YUNNAN JICUI BIO-TECH CO., LTD.

Effective date: 20140630

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20140630

Address after: 675000 Yongan Road, Chuxiong Development Zone, Yunnan, No. 161

Patentee after: JICUI HEALTH INDUSTRY CO., LTD.

Address before: 675000 Yongan Road, Chuxiong Development Zone, Yunnan, No. 161

Patentee before: Yunnan Jecui Biotechnology Co., Ltd.